Publication | Closed Access

Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer

Breast OncologyMedicinePathologyImmune Checkpoint InhibitorBreast CancerNeoadjuvant Trastuzumab-based ChemotherapyCancer TreatmentOncologyRadiation OncologyTumor BiologyHer2-positive Breast Cancer